{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:39:52Z","timestamp":1794249592564,"version":"4.9.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.xcrm.2024.101703","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T18:52:41Z","timestamp":1725043961000},"page":"101703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib"],"prefix":"10.1016","volume":"5","author":[{"given":"Arturo","family":"Simoni-Nieves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshit","family":"Lindzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvendu","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishita","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boobash-Raj","family":"Selvadurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Van Daele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Haga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Romaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomer-Meir","family":"Salame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirie","family":"Zerbib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roni","family":"Oren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Marrocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-7884","authenticated-orcid":false,"given":"Yosef","family":"Yarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2024.101703_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature13385","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101703_bib2","article-title":"Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer","volume":"9","author":"Negrao","year":"2021","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.xcrm.2024.101703_bib3","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.21037\/jtd.2019.11.04","article-title":"The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base","volume":"11","author":"Jiao","year":"2019","journal-title":"J.\u00a0Thorac. Dis."},{"key":"10.1016\/j.xcrm.2024.101703_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101703_bib5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101703_bib6","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.xcrm.2024.101703_bib7","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/ng.2330","article-title":"Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer","volume":"44","author":"Zhang","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2024.101703_bib9","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1158\/2159-8290.CD-12-0108","article-title":"HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation","volume":"2","author":"Takezawa","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101703_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx065","article-title":"An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression","volume":"109","author":"Schwarz","year":"2017","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.xcrm.2024.101703_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3224","article-title":"Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met","volume":"14","author":"Mueller","year":"2012","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib12","doi-asserted-by":"crossref","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","article-title":"Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations","volume":"68","author":"Yano","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib13","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib14","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib15","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","article-title":"Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer","volume":"36","author":"Ramalingam","year":"2018","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101703_bib16","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101703_bib17","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101703_bib18","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/onc.2009.198","article-title":"Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors","volume":"28","author":"Gazdar","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2024.101703_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2024.101703_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib21","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1158\/1078-0432.CCR-15-0560","article-title":"The allelic context of the C797S mutation acquired upon treatment with third generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies","volume":"21","author":"Niederst","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib22","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-023-05874-3","article-title":"Lung adenocarcinoma promotion by air pollutants","volume":"616","author":"Hill","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101703_bib24","first-page":"355","article-title":"SOS repair hypothesis: phenomenology of an inducible DNA repair which is accompanied by mutagenesis","volume":"5A","author":"Radman","year":"1975","journal-title":"Basic Life Sci."},{"key":"10.1016\/j.xcrm.2024.101703_bib25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A\u00a0chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib26","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent Cancer Cells: The Deadly Survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib27","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1158\/2159-8290.CD-22-0111","article-title":"AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer","volume":"12","author":"Noronha","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101703_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15205009","article-title":"Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators","volume":"15","author":"Marrocco","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101703_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaa0725","article-title":"Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer","volume":"8","author":"Mancini","year":"2015","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2024.101703_bib30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.15252\/emmm.201708076","article-title":"An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors","volume":"10","author":"Mancini","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib31","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1158\/1078-0432.CCR-18-0450","article-title":"A Combination of Approved Antibodies Overcomes Resistance of Lung Cancer to Osimertinib by Blocking Bypass Pathways","volume":"24","author":"Romaniello","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092394","article-title":"Targeting HER3, a Catalytically Defective Receptor Tyrosine Kinase, Prevents Resistance of Lung Cancer to a Third-Generation EGFR Kinase Inhibitor","volume":"12","author":"Romaniello","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.xcrm.2024.101703_bib33","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202013144","article-title":"Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models","volume":"13","author":"Marrocco","year":"2021","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib34","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib35","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1158\/0008-5472.CAN-20-3555","article-title":"Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors","volume":"81","author":"Haga","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib36","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41467-018-08074-0","article-title":"AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells","volume":"10","author":"Taniguchi","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.xcrm.2024.101703_bib38","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1158\/1078-0432.CCR-19-2321","article-title":"ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer","volume":"26","author":"Okura","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib39","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.21037\/tcr.2019.09.61","article-title":"Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer","volume":"8","author":"Wang","year":"2019","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib40","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","article-title":"A Convergence-Based Framework for Cancer Drug Resistance","volume":"33","author":"Konieczkowski","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib41","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib42","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1158\/2159-8290.CD-11-0106","article-title":"BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors","volume":"1","author":"Faber","year":"2011","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2024.101703_bib43","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.tiv.2007.03.003","article-title":"A mathematical approach to study combined effects of toxicants in\u00a0vitro: evaluation of the Bliss independence criterion and the Loewe additivity model","volume":"21","author":"Goldoni","year":"2007","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.xcrm.2024.101703_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004155","article-title":"The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells","volume":"6","author":"Meyer","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.xcrm.2024.101703_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ccell.2015.03.010","article-title":"AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR\/PKC\/mTOR axis in head and neck and esophageal squamous cell carcinomas","volume":"27","author":"Elkabets","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib46","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1083\/jcb.146.5.905","article-title":"Megabase chromatin domains involved in DNA double-strand breaks in\u00a0vivo","volume":"146","author":"Rogakou","year":"1999","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.xcrm.2024.101703_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2018.101084","article-title":"ROS and the DNA damage response in cancer","volume":"25","author":"Srinivas","year":"2019","journal-title":"Redox Biol."},{"key":"10.1016\/j.xcrm.2024.101703_bib48","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc2521","article-title":"Derailed endocytosis: an emerging feature of cancer","volume":"8","author":"Mosesson","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101703_bib49","doi-asserted-by":"crossref","first-page":"E973","DOI":"10.1152\/ajpendo.90857.2008","article-title":"Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases","volume":"296","author":"Abella","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.xcrm.2024.101703_bib50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2020.02.019","article-title":"Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies","volume":"180","author":"Chew","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib51","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","article-title":"Therapy-induced APOBEC3A drives evolution of persistent cancer cells","volume":"620","author":"Isozaki","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101703_bib52","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1126\/science.aav4474","article-title":"Adaptive mutability of colorectal cancers in response to targeted therapies","volume":"366","author":"Russo","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2024.101703_bib53","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-biochem-062917-012405","article-title":"Translesion and Repair DNA Polymerases: Diverse Structure and Mechanism","volume":"87","author":"Yang","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.xcrm.2024.101703_bib54","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/15384101.2018.1456296","article-title":"Diverse roles of RAD18 and Y-family DNA polymerases in tumorigenesis","volume":"17","author":"Yang","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.xcrm.2024.101703_bib55","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1073\/pnas.1019002108","article-title":"Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies","volume":"108","author":"Schaefer","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101703_bib56","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/protein\/9.7.617","article-title":"'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization","volume":"9","author":"Ridgway","year":"1996","journal-title":"Protein Eng."},{"key":"10.1016\/j.xcrm.2024.101703_bib57","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.molcel.2017.10.001","article-title":"Genetically Encoded Tools for Optical Dissection of the Mammalian Cell Cycle","volume":"68","author":"Sakaue-Sawano","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2024.101703_bib59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2024.101703_bib60","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4939-8958-4_2","article-title":"Cancer Immunotherapy: The Dawn of Antibody Cocktails","volume":"1904","author":"Marrocco","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.xcrm.2024.101703_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5640","article-title":"MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations","volume":"8","author":"Arena","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib62","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/cbt.25191","article-title":"Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer","volume":"14","author":"Al-Marrawi","year":"2013","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.xcrm.2024.101703_bib63","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science (New York, N Y)"},{"key":"10.1016\/j.xcrm.2024.101703_bib64","article-title":"Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer","volume":"14","author":"Lin","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.xcrm.2024.101703_bib65","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1073\/pnas.1220763110","article-title":"Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR","volume":"110","author":"Ferraro","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2024.101703_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188927","article-title":"Epidermal growth factor receptor PROTACs as an effective strategy for cancer therapy: A review","volume":"1878","author":"Wang","year":"2023","journal-title":"Biochim. Biophys. Acta. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2024.101703_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105605","article-title":"Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in\u00a0vivo efficacy","volume":"120","author":"Shi","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.xcrm.2024.101703_bib68","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nature01965","article-title":"Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation","volume":"425","author":"Stelter","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2024.101703_bib69","article-title":"L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: comparison of osimertinib versus cetuximab","volume":"4","author":"Marrocco","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.xcrm.2024.101703_bib70","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41588-023-01592-8","article-title":"The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance","volume":"56","author":"Caswell","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2024.101703_bib71","doi-asserted-by":"crossref","first-page":"W488","DOI":"10.1093\/nar\/gkaa216","article-title":"SynergyFinder 2.0: visual analytics of multi-drug combination synergies","volume":"48","author":"Ianevski","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.xcrm.2024.101703_bib72","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","article-title":"Prediction of drug combination effects with a minimal set of experiments","volume":"1","author":"Ianevski","year":"2019","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.xcrm.2024.101703_bib73","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s12859-021-04344-9","article-title":"CellProfiler 4: improvements in speed, utility and usability","volume":"22","author":"Stirling","year":"2021","journal-title":"BMC Bioinf."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379124004245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,3]],"date-time":"2024-11-03T02:21:38Z","timestamp":1730600498000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379124004245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":72,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2666379124004245"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101703","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2024.101703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101703"}}